Physician profile
John Paik
NPI 1619131299
$9,262.18
in general payments reported to CMS, 2019-2025
44 companies · $663 in 2025
The $663 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,579 · 2020: $1,046 · 2021: $1,448 · 2022: $1,904 · 2023: $1,664 · 2024: $959 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,285.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,294.53 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $1,014.76 | 2019-2024 | Farxiga, Airsupra, Fasenra |
| Abbvie INC. | $868.14 | 2019-2025 | |
| Glaxosmithkline, LLC. | $814.98 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $510.38 | 2019-2025 | |
| Lilly USA, LLC | $506.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $429.74 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $324.57 | 2020-2023 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.30 | 2019-2024 | Jardiance |
| Inspire Medical Systems, INC. | $285.96 | 2020-2025 | Inspire |
| Allergan, INC. | $267.37 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $254.08 | 2019-2024 | Trintellix |
| Amgen INC. | $251.03 | 2019-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $198.55 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $197.99 | 2021-2023 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Paik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.